0 57

Cited 0 times in

Cited 0 times in

Foritinib, a type II ROS1 inhibitor for NSCLC

DC Field Value Language
dc.contributor.author이기쁨-
dc.date.accessioned2025-07-09T08:36:29Z-
dc.date.available2025-07-09T08:36:29Z-
dc.date.issued2024-09-
dc.identifier.issn2213-2600-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/206525-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford Elsevier-
dc.relation.isPartOfLANCET RESPIRATORY MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Agents / therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / genetics-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHLung Neoplasms* / genetics-
dc.subject.MESHProtein Kinase Inhibitors / therapeutic use-
dc.subject.MESHProtein-Tyrosine Kinases* / antagonists & inhibitors-
dc.subject.MESHProto-Oncogene Proteins* / genetics-
dc.titleForitinib, a type II ROS1 inhibitor for NSCLC-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJii Bum Lee-
dc.contributor.googleauthorSai-Hong Ignatius Ou-
dc.identifier.doi10.1016/S2213-2600(24)00210-8-
dc.contributor.localIdA05930-
dc.relation.journalcodeJ03364-
dc.identifier.eissn2213-2619-
dc.identifier.pmid39059399-
dc.identifier.urlhttps://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213260024002108-
dc.contributor.alternativeNameLee, Jii Bum-
dc.contributor.affiliatedAuthor이기쁨-
dc.citation.volume12-
dc.citation.number9-
dc.citation.startPage656-
dc.citation.endPage657-
dc.identifier.bibliographicCitationLANCET RESPIRATORY MEDICINE, Vol.12(9) : 656-657, 2024-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.